PRODUCT INFORMATION

BP-1-102

Item No. 28368

CAS Registry No.:	1334493-07-0
Formal Name:	4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-2-hydroxybenzoic acid
MF:	$C_{29}H_{27}F_5N_2O_6S$
FW:	626.6
Purity:	≥98%
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BP-1-102 is supplied as a crystalline solid. A stock solution may be made by dissolving the BP-1-102 in the solvent of choice, which should be purged with an inert gas. BP-1-102 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of BP-1-102 in these solvents is approximately 15 and 10 mg/ml, respectively.

Description

BP-1-102 is an inhibitor of STAT3.[1] It binds to STAT3 (K_d = 504 nM) and inhibits STAT3 binding to an IL-6R/gp130 peptide in a fluorescence polarization assay (IC_{50} = 4.1 µM). BP-1-102 (10-30 µM) decreases viability and proliferation of STAT3-dependent NIH3T3/v-Src, MDA-MB-231, PANC-1, DU145 and A549 cancer cells, but not STAT3-independent NIH3T3, NIH3T3/vRas, TE-71, and A2780S cancer cells. It reduces tumor growth and inhibits expression of the STAT3-dependent genes encoding c-Myc, survivin, Bcl-xL, cyclin D1, and VEGF in MDA-MB-231 and A549 mouse xenograft models when administered at doses of 1 and 3 mg/kg.

Reference

1. Zhang, X., Yue, P., Page, B.D., *et al.* Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. *Proc. Natl. Acad. Sci. USA.* **109(24)**, 9623-9628 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM